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Abstract: In the last decade, researchers have gained a greater understanding of the 
pathophysiologic mechanisms of type 2 diabetes as a chronic and progressive disease. One of 
the more recent treatment targets is the kidney. The kidneys become maladaptive in diabetes 
by increasing the reabsorption of glucose above the normal physiologic renal threshold. This 
discovery has led to the development of the sodium/glucose cotransporter 2 inhibitors (SGLT2). 
These agents readjust the renal threshold for glucose reabsorption to a lower level and decrease 
glucose reabsorption, while increasing urinary glucose when the glucose is above the renal 
threshold and subsequently lowering plasma glucose. The mechanism of action of the SGLT2 
inhibitors is insulin independent, which makes them a novel treatment of diabetes. At the time 
of preparation of this manuscript, there were three SGLT2 inhibitors available in the US. This 
manuscript focuses on empagliflozin, the newest SGLT2 inhibitor, the trials in its development, 
and the clinical data available to date. Further, the authors propose future applications of empagli-
flozin, including in the treatment of type 1 diabetes, and its potential role in renoprotection.
Keywords: SGLT-2 inhibitors, empagliflozin, type 2 diabetes, kidneys, type 1 diabetes, 
glucosuria
Introduction
Type 2 diabetes mellitus (T2DM) has become a global pandemic. It is now estimated 
that nearly 387 million people have diabetes globally.1 Rates in developing countries are 
increasing due to the changes in rates of obesity and inactivity. Deaths from diabetes are 
projected to increase 50% worldwide by 2025. Eighty percent of these deaths will occur 
in low and middle income countries.2 T2DM is a complex and progressive disease. Once 
thought of as only a disease of insulin resistance, it is now believed that there are at least 
eight pathologic processes that lead to type 2 diabetes.3 These include abnormal β-cell 
insulin secretion, excessive α-cell glucagon production, abnormal incretin effect, insulin 
resistance at the peripheral tissues, increased hepatic glucose production, increased 
lipolysis, neurotransmitter dysfunction, and abnormal renal handling of hyperglycemia.3 
Knowledge of these pathophysiologic mechanisms is critical in the development and 
use of targeted treatments that have complementary mechanisms of action.
Insulin resistance is usually maximal at the time a person is diagnosed with T2DM. 
β-cell dysfunction and failure become prominent defects in this progressive disease. 
As T2DM is a multisystemic and progressive disease, no single therapy is adequate 
for long-term control. Treatment must be multifactorial, and combination therapy is 
often necessary. Most of the current available treatments are insulin “centric”, mean-
ing that they need insulin production to provide therapeutic benefit. These therapies 
only have a therapeutic effect as long as there is measurable insulin production. One 
of the newly discovered pathophysiologic processes that can be treated is increased 
renal glucose reabsorption that occurs in diabetes.4 This treatment is novel because 
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the kidney has not been a therapeutic target previously, and 
the mechanism of action is independent of insulin.
Introduction to renal glucose 
physiology
Plasma glucose is usually maintained in a relatively narrow 
range between 70 and 160 mg/dL (3.9 and 8.9 mmol/L). 
This involves a delicate balance between glucose production 
(liver and kidney), intestinal absorption, renal reabsorp-
tion, and glucose utilization in tissues around the body. 
In a normal healthy adult, kidneys can filter 160–180 g of 
glucose/d (mean glucose 100 mg/dL ×180 L/d).5,6 In eugly-
cemic people, essentially all the filtered glucose is reabsorbed 
in the proximal convoluted tubule allowing the glucose to 
remain in circulation. The normal filtered glucose load in a 
person without diabetes is approximately 125 mg/min, but 
can rise when the ambient glucose rises or if the glomerular 
filtration rate increases. The maximum renal threshold for 
glucose reabsorption occurs when the serum glucose is 
approximately 180–200 mg/dL. In these individuals, when 
the glucose exposure to the kidney exceeds 200 mg/dL 
(11.0 mmol/L), no additional glucose is reabsorbed and the 
excessive glucose is excreted in the urine.6
Glucose reabsorption is mediated by the sodium/glucose 
cotransporter (SGLT) proteins. This process is independent of 
insulin.7 The great majority of the filtered glucose (90%) is reab-
sorbed in the first segment of the proximal convoluted tubule by 
SGLT2. SGLT2 is a low affinity but high capacity transporter.8 
The remaining filtered glucose (10%) is removed from the fil-
trate by SGLT1 in the distal aspect of the proximal convoluted 
tubule. SGLT1 is a high-affinity and low-capacity transporter.8 
This mechanism allows for conservation of calories.
There are a number of SGLT proteins expressed through-
out the body.8 SGLT1 is expressed in the small intestine and 
helps to regulate glucose and galactose absorption in the 
kidney as mentioned before. People who do not have func-
tioning SGLT1 will suffer from significant gastrointestinal 
(GI) complications including severe diarrhea, while those 
without functioning SGLT2 appear to live normal lives 
despite increased glucosuria. The SGLT2 inhibitors work on 
the SGLT1 and SGLT2 proteins. Therefore, high selectivity 
toward SGLT2 may be pharmacologically beneficial. Dual 
blockade may provide an even greater therapeutic effect, 
but it will need to be balanced with the GI effects of SGLT1 
blockade (Figure 1).
Renal physiology in type 2 diabetes
People with T2DM routinely experience both fasting and 
postprandial hyperglycemia, which is a result of a number of 
maladaptive physiological responses that include exaggerated 
hepatic and renal glucose production, impaired insulin secre-
tion, and inefficient glucose uptake.3 Recently, the kidney’s 
maladaptive response to chronic hyperglycemia has become 
a treatment target in diabetes.
Normal renal physiology dictates that all filtered glucose 
is reabsorbed. However, if the plasma glucose levels rise 
above 200 mg/dL (11 mmol/L) as seen in diabetes, some 
glucose is excreted in the urine. As shown in diabetic mice, 
there is upregulation of SGLT2. This might contribute to 
the increased plasma glucose threshold before any glucose 
is seen in the urine.9
However, in mouse models of diabetes mellitus, there 
is upregulation of SGLT2 in response to chronic hypergly-
cemia, allowing more glucose reabsorption.10 Furthermore, 
there is also an increase in SGLT protein expression in dia-
betes.11 These combine to potentially increase the maximum 
renal glucose threshold which contributes to more glucose 
reabsorption, which maintains plasma hyperglycemia 
(Figure 2).
Early attempts to address abnormal 
renal physiology via SGLT proteins
More than 100 years ago, it was identified that a botanical 
agent could induce glucosuria. The active ingredient was later 
identified as phlorizin, a substance found in the bark of apple 
trees.12,13 Unfortunately, phlorizin had a number of significant 
limitations that made it unviable as a pharmacologic treat-
ment. It had little selectivity for SGLT2 over SGLT1. The 
SGLT1 activity resulted in significant GI side effects. Further, 
phlorizin has an O-glucosidase which makes it susceptible 
to degradation by the β-glucosidase in the intestine, so it 
required IV dosing.14
Empagliflozin is structurally similar to phlorizin but 
with some important differences. It has a C-glucoside 
with a carbon–carbon bond between the glucose and 
aglycone moiety. This makes it resistant to degradation 
in the GI tract, allowing it to be orally administered.15 
Further, because empagliflozin (EMPA) is highly selec-
tive for SGLT2 (2,500-fold), it is less likely to have GI 
side effects.7
The glucosuric effects of SGLT2 blockade raised early 
concerns about the safety of chronic high glucose levels in 
the renal tubules and in the urine. In familial renal gluco-
suria, people have nonfunctioning SGLT2 proteins from a 
mutation of the SLC5A2 gene that encodes SGLT2. These 
patients have chronic glucosuria even in the face of nor-
moglycemia. Individuals with this condition rarely suffer 
from glucose-related problems and have no known renal 
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Figure 1 Physiology of glucose reabsorption in the proximal convoluted tubule.
Note: Reproduced from Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res. 
2015;12(2):78–89,6 copyright ©2015 by (SAGE Publications). Reprinted by Permission of SAGE Publications, Ltd.
Abbreviations: GLUT, glucose transporter; PT, proximal tubule; KCNE1, potassium voltage-gated channel Isk-related family member 1; KCNQ1, potassium voltage-gated 
channel KQT-like subfamily member 1; SGLT, sodium-dependent glucose transporter.
tubular dysfunction and typically do not report increased 
genitourinary infections.16
Conversely, loss of function of SGLT1 from a mutation 
of SLC5A1 results in little to no glucosuria but significant GI 
symptoms because of the glucose–galactose malabsorption 
that results in watery diarrhea and potentially dehydration.17 
Thus, preferential targeting SGLT2 proteins (rather than 
SGLT1) with pharmacologic intervention is preferable.
SGLT2 inhibitors
The SGLT2 inhibitors are a new drug class that address 
hyperglycemia by reducing renal glucose reabsorption, 
increasing urinary glucose excretion, and consequentially 
reducing serum glucose levels.18,19 The SGLT2 inhibitors 
work independent of insulin (both secretion and sensitivity), 
which makes this class novel and potentially complementary 
to most current diabetes therapies.
There are currently three SGLT2 inhibitors available in 
the US. Canagliflozin was approved by the US Food and 
Drug Administration (FDA) in March 2013 (FDA news 
release 2013),20 dapagliflozin in January 2014, and EMPA 
in August of 2014.21 All of these agents are potent competi-
tive inhibitors of the SGLT2 protein, but dapagliflozin and 
EMPA are highly selective for SGLT2, while canagliflozin 
has dual blockade of SGLT1 and SGLT2. Of the three com-
mercially available SGLT2 inhibitors, EMPA has the highest 
selectivity for SGLT2 (2,500-fold) compared to SGLT1.22 
The chemical structure for EMPA is shown in Figure 3.
Preclinical studies
Preclinical studies showed that EMPA is a competitive 
inhibitor of the SGLT2, has high specificity to SGLT2, and 
has a half-life of approximately 60 minutes. Early cell line 
studies demonstrated that EMPA is a potent inhibitor of 
SGLT2 and has 2,500-fold sensitivity for inhibition of 
SGLT2 vs SGLT1.23 Subsequent rodent studies showed that 
EMPA reduced blood glucose in a dose-dependent manner 
by increasing urinary glucose excretion.22 In one 5-week 
 
D
ru
g 
De
sig
n,
 D
ev
el
op
m
en
t a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
98
.1
42
.1
24
.1
10
 o
n 
07
-S
ep
-2
01
6
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Drug Design, Development and Therapy 2015:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
5796
Shubrook et al
trial, EMPA reduced HbA
1c
 levels by 0.3% (1 mg/kg) and 
1.1% (3 mg/kg).24
Human Phase I studies
A single dose of EMPA was studied in 72 healthy males.25 
Subjects were randomized to placebo or a dose of EMPA 
between 0.5 and 800 mg. EMPA was quickly absorbed 
with a maximum plasma concentration at approximately 
1.5–2.1 hours, with drug exposure proportional to the dose 
administered. EMPA had a biphasic decline in concen-
tration in the decay phase, with a terminal half-life from 
8.6–13.1 hours.22 In these studies, the urinary glucose excre-
tion increased to a maximum at the 50 mg dose, significantly 
higher than placebo.25 Food and postprandial state had no 
effect on drug absorption, and glucosuria was similar after 
meals in these healthy subjects. All side effects were similar 
to placebo (headaches, GI, and nervous system disorders) 
and were not dose dependent. One hypoglycemic event was 
reported (glucose 53 mg/dL [2.9 mmol/L]) during a 3-hour 
glucose tolerance test.
Another series of Phase I trials tested EMPA 1–100 mg 
in 48 healthy Japanese men.26 In these studies, EMPA was 
rapidly absorbed with a maximum concentration at around 
1.25–2.5 hours, with drug exposure and clearance relative to 
the dose administered. EMPA exposure was approximately 
1.5 times higher in this study possibly due to differences in 
body weight between the population studies. The urinary 
glucose clearance was dose dependent as well. EMPA was 
? ?
?
??
??
??
??
??
Figure 3 Chemical structure of empagliflozin (Jardiance®).
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Figure 2 Downstream renal effects of SGLT1 and SGLT2 inhibition.
Note: Reproduced from Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res. 
2015;12(2):78–89,6 copyright ©2015 by (SAGE Publications). Reprinted by Permission of SAGE Publications, Ltd.
Abbreviations: GLUT, glucose transporter; SGLT, sodium glucose transporter; PT, proximal tubule; LOH, loop of Henle; DT, distal tubule; CD, collecting duct; NHE3, 
sodium hydrogen exchanger-3; EGP, endogenous glucose production; SNGFR, single nephron glomerular filtration rate; TGF, tubuloglomerular feedback.
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well tolerated (mild side effects, not dose dependent), and 
no hypoglycemia was reported.
Finally, the pharmacokinetic (PK) and pharmacodynam-
ics (PDs) profiles of EMPA were determined after the first 
dose on day 1 and at steady state dosing on day 28. EMPA 
was rapidly absorbed with peak concentration at 1.5 hours. 
Clearance was biphasic with a range of 13.2–16.5 hours. 
Oral clearance showed linear PKs in terms of time. 
Eighteen percent of the medication was excreted in the 
urine unchanged. The urinary glucose excretion was dose 
dependent. Compared to baseline, urinary glucose excre-
tion increased to 74 g in the 10 mg dose, 90 g in the 25 mg 
dose, and 81 g in the 100 mg dose. There was essentially no 
change in urinary glucose excretion in the placebo group. 
Urinary glucose excretion remained constant throughout the 
study. No significant changes in urine volume were reported. 
There were significant reductions in fasting and post oral 
glucose tolerance test glucose readings on day 28 compared 
to placebo. A nonsignificant reduction in HbA
1c
 was seen in 
the EMPA groups at 28 days (Table 1).27,28
Phase II trials
A study evaluated the safety, tolerability, and PK/PD in 78 
people with type 2 diabetes.27 Subjects were randomized to 
EMPA (10, 25, 100 mg) or placebo. Weighted randomization 
was completed for the 100 mg dose (2× other groups) to assess 
the safety of this dose. The plasma concentration and urinary 
glucose excretion were dose dependent. Urinary glucose 
excretion remained elevated throughout the trial compared 
to no increase in the placebo-treated group. Side effects were 
similar in the treatment arms, with the most common adverse 
effects being pollakiuria (10.3%), nasopharyngitis (9.0%), 
constipation (9.0%), and headache (7.7%). Urinary-related 
adverse effects were more common in the EMPA groups.
In another study, investigators randomized 408 treatment 
naïve (or 4-week washout) subjects with type 2 diabetes to 
EMPA 25 mg, metformin, or placebo. The overall mean A
1c
 
was 7.9%±0.8% at entry. All EMPA doses had significant 
A
1c
 reductions compared to placebo (placebo +0.1%; EMPA 
5 mg, -0.4%; 10 mg, -0.5%; 25 mg, -0.6%; all P0.0001) 
and showed similar reduction as compared with metformin 
(-0.7%).29
A trial evaluated the PK/PD of a single dose of 50 mg of 
EMPA in 40 patients with various levels of renal impairment. 
The peak concentration was similar to previous studies, but 
the total plasma exposure and maximum concentration were 
slightly elevated in those with advanced renal impairment. 
In this study, the greater the renal impairment, the lower the 
urinary glucose excretion.30
There was some initial concern about hepatic safety in 
early studies with dapagliflozin. In a similar set of studies 
with EMPA (as already mentioned), there did not appear to 
be any dose adjustment needed in people with mild, moder-
ate, or severe hepatic impairment.31 These studies are sum-
marized in Table 2.
Some small studies have reported an increase in endo-
genous glucose production with SGLT2 inhibitors including 
EMPA.32–34 The elevated hepatic glucose production appears 
to be a compensatory response to support normal plasma 
glucose levels in the presence of sustained urinary glucose 
excretion. The plasma glucagon/insulin ratio is a regulator 
of hepatic glucose production and so the increase in glu-
cagon could explain the rise in hepatic glucose production 
observed with SGLT2 inhibition.33 Overall, glucose levels 
are still decreased despite the increase in glucose production. 
Further investigation is needed to determine the long-term 
significance of this physiologic response and optimal thera-
peutic approach.
Clinical benefits of empagliflozin in Phase 
iii trials
Empagliflozin has been studied as a monotherapy and in 
combination therapy for type 2 diabetes. A
1c
 reduction with 
EMPA 10 mg (-0.66%) or 25 mg (-0.78%) was statistically 
superior to that observed with placebo (0.08%) when given 
as monotherapy.35 A
1c
 reduction with EMPA 10 and 25 
mg was similar to A
1c
 reduction with sitagliptin 100 mg.35 
In this study, body weight decreased significantly with 
EMPA 10 mg (-2.26 kg) and 25 mg (-2.46 kg) compared 
to placebo (-0.33 kg). Finally, systolic blood pressure 
(SBP) decreased significantly with EMPA 10 mg (-2.9 
mmHg) and 25 mg (-3.7 mmHg) compared to placebo 
(-0.3 mmHg).
Table 1 Summary of key pharmacokinetic parameters of empag-
liflozin 10 and 25 mg at steady state after oral dosing
Pharmacokinetic  
parameters
Empagliflozin dose
10 mg qd (n=8) 25 mg qd (n=9)
AUC0–t, ss (nmol h/L) 2,030 (362) 4,990 (1,080)
Cmax, ss (nmol h/L) 283 (90.1) 630 (106)
tmax, ss (h)
a 1.5 (1.0–2.0) 2.0 (0.7–4.2)
t1/2, ss (h) 14.3 (2.4) 10.7 (2.1)
Fe0–24, ss (%) 18.7 (4.5) 12.7 (6.4)
CLR, t, ss (mL/min) 34.4 (7.9) 23.5 (8.7)
Notes: Data are mean (SD) unless otherwise indicated. aMedian (range) is denoted. 
Reproduced from McGill J. The SGLT2 inhibitor empagliflozin for the treatment of 
type 2 diabetes mellitus: a bench to bedside review. Diabetes Ther. 2014;5:43–63.57
Abbreviations: AUC, area under concentration–time curve; Cmax, maximum plasma 
concentration; CLR, renal clearance; Fe, fraction of dose that was excreted unchanged 
in urine; qd, once daily; SD, standard deviation; ss, steady state; t, dosing interval; 
t1/2, terminal half-life in plasma; tmax, time to maximum plasma concentration.
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Nearly two-thirds of the subjects in this study entered 
the extension phase of the study for an additional 52 weeks 
for a total of 76 weeks. The placebo-subtracted A
1c
 reduc-
tions at 76 weeks were 0.78% for EMPA 10 mg, 0.89% for 
EMPA 25 mg, with persistent weight loss of 1.8 kg with 
10 mg of EMPA and 2.0 kg for 25 mg of EMPA and SBP 
reductions of 3.4 mmHg in both the 10 and 25 mg arms 
of EMPA.36
As add-on therapy to metformin, EMPA 25 mg has been 
shown to be statistically superior to glimepiride in a 104-week 
study.37 The A
1c
 reduction was 0.66% with EMPA and 0.55% 
with glimepiride. Weight and blood pressure were reduced 
with EMPA (-3.1 kg, -3.1 mmHg), and these changes were 
not seen with glimepiride (+1.3 kg, +2.1 mmHg).
When EMPA was given in combination with other 
medications, there were significant improvements in HbA
1c
. 
Table 3 provides an overview of EMPA with metformin38,39 
metformin plus a sulfonylurea,38 pioglitazone or pioglita-
zone plus metformin,40 or multidose insulin with or without 
metformin.41
Statistically significant reductions in body weight 
and SBP (relative to placebo) were also found in EMPA 
combination studies. These studies included combinations 
with metformin,37–40 with metformin plus a sulfonylurea,37 
and with pioglitazone or pioglitazone plus metformin.40 
When EMPA 10 mg or 25 mg were added to multidose 
insulin with or without metformin, there was a statistically 
significant reduction in body weight but a nonsignificant 
reduction in SBP.41 In combination with metformin, EMPA 
25 mg resulted in statistically significant reductions in body 
weight and SBP compared with glimepiride.39
EMPA in combination studies resulted in small 
increases in low-density lipoprotein cholesterol (LDL-C) 
and high-density lipoprotein cholesterol (HDL-C). When 
EMPA was added to metformin plus pioglitazone, there 
were small increases in HDL-C in placebo-controlled 
studies: 0.06 mmol/L (2.32 mg/dL) with EMPA 10 mg 
and 0.03 mmol/L (1.16 mg/dL) with EMPA 25 mg.37 With 
metformin only, increases in HDL-C of 0.08 mmol/L 
(3.09 mg/dL) and 0.06 mmol/L (2.32 mg/dL) with EMPA 
10 and 25 mg, respectively, were seen relative to placebo.36 
EMPA as an add-on to metformin has been reported to 
result in small increases in LDL-C (adjusted mean increase 
0.15 mmol/L).40 Finally, Phase III studies with EMPA have 
shown reductions in plasma uric acid.33,35,37 This may be 
clinically important in that hyperuricemia has been identified 
as an independent risk factor for cardiovascular disease.42
EMPA was also studied in people with moderate renal 
insufficiency. EMPA 25 mg resulted in an adjusted mean 
placebo subtracted A
1c
 change of -0.42% at week 24 in 
patients with estimated glomerular filtration rate (eGFR) 30 
to 60 mL/min/1.73 m2.43 In patients with stage 2 and 3 
chronic kidney disease, EMPA resulted in significant reduc-
tions of A
1c
, body weight, and SBP compared with placebo 
after 52 weeks.43
Results from these EMPA studies are consistent with 
results seen from other agents within the class. A systematic 
review and meta-analysis of clinical trials comparing an 
SGLT2 inhibitor with placebo (45 studies, n=11,232) or an 
active comparator (13 studies, n=5,175) reported improved 
glycemic control, reduced body weight, and reduced blood 
pressure with SGLT2 inhibitor therapy.44
Safety of empagliflozin
The most frequently occurring adverse events with EMPA are 
urinary tract infections (7.6% with placebo vs 9.3% and 7.6% 
with EMPA 10 and 25 mg, respectively) and genital mycotic 
infections (in female patients: 1.5% with placebo vs 5.4% 
and 6.4% with EMPA 10 and 25 mg, respectively).23 Adverse 
events related to osmotic diuresis and volume contraction 
Table 2 Empagliflozin pharmacokinetics after administration of a single 50 mg dose in patients with renal or hepatic impairment
Impairment severity Total plasma exposure AUC0–∞ (nmol h/L) Cmax, ss (nmol/L)
Renal impairment study57
Mild (n=9) 118.2% (96.2, 145.4) 118.8% (93.6, 150.8)
Moderate (n=7) 119.9% (96.3, 149.5) 102.3% (79.3, 131.9)
Severe (n=8) 166.3% (134.4, 205.7) 120.7% (94.4, 154.3)
Failure/eSRD (n=8) 148.3% (119.9, 183.4) 103.8% (81.2, 132.6)
Hepatic impairment study30
Mild (n=8) 123.15% (98.9, 153.4) 103.8% (82.3, 131.0)
Moderate (n=8) 146.97% (118.0, 183.0) 123.3% (97.7, 155.6)
Severe (n=8) 174.70% (140.3, 217.6) 148.4% (117.7, 187.2)
Notes: For both studies, values are adjusted GMR (impaired/normal group), with 90% CI for adjusted GMR. Reproduced from McGill J. The SGLT2 inhibitor empagliflozin 
for the treatment of type 2 diabetes mellitus: a bench to bedside review. Diabetes Ther. 2014;5:43–63.57
Abbreviations: AUC, area under the concentration–time curve; CI, confidence interval; Cmax, ss, maximum plasma concentration at steady state; ESRD, end-stage renal 
disease; GMR, geometric mean ratio.
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have been evaluated from pooled data from Phase I, II, 
and III studies in 11,000 patients.45 In that analysis, the 
overall incidence of volume depletion events was 1.4% with 
EMPA 10 mg and 1.5% with EMPA 25 mg vs 1.4% with 
placebo. The incidence of these events was higher in subjects 
aged 75 years, those with eGFR 30 mL/min/1.73 m2, 
and those also receiving diuretic therapy.21
Increased rates of hypoglycemia were not seen in EMPA 
monotherapy or in combination with insulin sensitizers. How-
ever, when combined with other medications that have a high 
risk of hypoglycemia (sulfonylureas or insulin), the EMPA 
arms of these studies had higher rates of hypoglycemia.38,40,41
Recent updates
Empagliflozin and glucagon
Ferrannini et al34 demonstrated that those people with type 
2 diabetes who took an SGLT2 inhibitor had an increase in 
glucagon and hepatic glucose production. This has a potential 
explanation (that Bonner et al46 recently published) in that 
there is SGLT2 expression in the α-cells in the pancreas. 
This will need further investigation. Clinically, it may be 
important to pair SGLT2 inhibitors that counteract this 
increase in glucagon such as dipepitdyl-peptidase -4 inhibi-
tor (DPP-4) inhibitors or glucaogon like peptide 1 receptor 
agonist (GLP-1 RA).
Empagliflozin/linagliptin-fixed dose 
combination
Empagliflozin has been recently approved (February 2015) 
in a combination therapy with linagliptin (LINA) (a DPP-4 
inhibitor).47 This medication, under the brand name 
Glyxambi® (Boehringer Ingelheim Pharmaceuticals, Inc., 
Ridgefield, CT, USA), is available as 10 mg EMPA/5 mg of 
LINA or 25 mg empagliflozin/5 mg of LINA.44 Boehringer 
Ingelheim manufactures both EMPA and LINA.
In a study, EMPA 25/LINA 5 mg (n=134) and EMPA/
LINA 10 mg/5 mg (n=135) were utilized in drug-naïve 
type 2 diabetes with a baseline HbA
1c
 of 7.99% and 8.04%, 
respectively. HbA
1c
 improved by 1.08% (EMPA/LINA 
25 mg/5 mg) and 1.24% (EMPA/LINA 10 mg/5 mg) and 
Table 3 Efficacy and safety of EMPA in randomized, double-blind Phase III trials of patients with type 2 diabetes mellitus
Study Regimen and duration Efficacy Safety
A1c (%) Body  
weight (kg)
SBP  
(mmHg)
UTIs (%) Events consistent  
with GMIs (%)
Events consistent 
with UTIs (%)
Monotherapy
Roden et al35 eMPA 10 mg (n=224)
eMPA 25 mg (n=87)
PBO (n=228)
24 weeks
-0.66
-0.78
0.08
-2.26
-2.48
-0.33
-2.9
-3.7
-0.3
6
4
4
3 M, 4 F
1 M, 9 F
0 M, 0 F
2 M, 15 F
1 M, 13 F
2 M, 9 F
Combination therapy
Häring et al37 MeT + SU + one of:
eMPA 10 mg (n=225)
eMPA 25 mg (n=216)
PBO (n=225)
24 weeks
-0.82
-0.77
-0.17
-2.16
-2.39
-0.39
-4.1
-3.5
-1.4
9.4
6.9
6.7
0.9 M, 4.5 F
0.9 M, 3.9 F
0.9 M, 0.9 F
2.7 M, 18.0 F
0 M, 17.5 F
2.7 M, 13.3 F
Häring et al38 MeT + one of:
eMPA 10 mg (n=217)
eMPA 25 mg (n=213)
PBO (n=207)
 24 weeks
-0.70
-0.77
-0.13
-2.08
-2.46
-0.45
-4.5
-5.2
-0.4
5.1
5.6
4.9
0.8 M, 7.6 F
0.8 M, 9.7 F
0 M, 0 F
0 M, 12.0 F
0.8 M, 11.8 F
2.6 M, 7.7 F
Ridderstråle et al39 MeT + one of:
eMPA 25 mg (n=765)
GLIM 1–4 mg (n=780)
104 weeks
-0.66
-0.55
-3.1
1.3
-3.1
2.5
14
13
9 M, 15 F
1 M, 3 F
7 M, 22 F
5 M, 23 F
Kovacs et al40 PiO ± MeT + one of:
eMPA 10 mg (n=165)
eMPA 25 mg (n=168)
PBO (n=165)
24 weeks
-0.59
-0.72
-0.11
-1.62
-1.47
0.34
-3.14
-4.00
0.72
1
4.5
10.7
10.9
7.2 M, 9.8 F
1.2 M, 6.0 F
1.4 M, 3.3 F
3.6 M, 30.5 F
2.4 M, 21.7 F
8.2 M, 22.8 F
Note: Adapted with permission from Miller E, Shubrook JH. Role of the kidneys and sodium glucose co-transporter 2 (sglt2) inhibitors in the treatment of type 2 diabetes 
mellitus. Osteopathic Family Physician. 2015;1(5):10–30.58 Copyright © 2015.
Abbreviations: EMPA, empagliflozin; F, female; GLIM, glimepiride; GMI, genital mycotic infections; M, male; MET, metformin; PBO, placebo; PIO, pioglitazone; SBP, systolic 
blood pressure; SU, sulfonylurea; UTI, urinary tract infection.
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body weight reductions of 2.0 and 2.7 kg were seen.48 
More people achieved an HbA
1c
 of less than 7% at 24 and 
52 weeks in the combination therapy than the individual 
medications.48
This study group also completed a trial with fixed-dose 
EMPA/LINA as add-on to metformin. In this 52 week trial, 
subjects were randomized to EMPA/LINA 25 mg/5 mg 
(n=137), EMPA/LINA 10 mg/5 mg (n=136), or the individual 
medications, EMPA 25 (n=141), EMPA 10 mg (n=140), or 
LINA 5 mg (n=132). The fixed combinations had greater 
A
1c
 reductions despite slightly lower starting A
1c
s. EMPA/
LINA 25 mg/5 mg reduced A
1c
 by 1.19%, and EMPA/LINA 
10 mg/5 mg reduced A
1c
 by 1.08%. The single agents reduced 
A
1c
 0.63%, 0.66%, and 0.7%, respectively. Weight loss was 
similar in the fixed combination groups and single agent 
EMPA. The 24-week weight loss was 3.0 kg in EMPA/LINA 
25 mg/5 mg, 2.6 kg in EMPA/LINA 10 mg/5 mg, 3.2 kg 
in EMPA 25 mg, 2.5 kg in EMPA 10 mg, and 0.7 kg in 
LINA 5 mg.49
Hypoglycemic risk and adverse reactions, such as urinary 
tract infections, pancreatitis, and cholesterol changes were 
monitored in the aforementioned trials.48,49 Results demon-
strated that there was no increase in severe hypoglycemia 
even with the fixed dose combination. There was no increase 
or change in adverse reactions when these two medications 
were administered simultaneously vs their individual adverse 
reaction profiles.48,49
Empagliflozin and renal indices
When the SGLT2 inhibitors were first released, there was 
some clinical concern that permissive glucosuria would 
contribute to advancing nephropathy despite some reas-
surance from the experience of people with familial renal 
glucosuria. In early clinical studies, there is some evidence 
that the contrary may be true. In a series of studies, patients 
with type 2 diabetes with preexisting microalbuminuria were 
randomized to EMPA 10, 25 mg, or placebo. Those on EMPA 
had reported decreased urinary albumin to creatinine ratio 
by 30% and 25%, respectively, compared to placebo.50 This 
suggests that despite permissive hyperglycemia, there may 
be some renoprotection from this class of medications. This 
is still exploratory and would need to be repeated.
Another study51 explored the effect of EMPA on the intra-
glomerular hemodynamic profile and hyperfiltration in patients 
with type 1 diabetes. In this study,52 27 patients who had hyper-
filtration but no hypertension or albuminuria, and 13 who had a 
normal GFR (and no hypertension/albuminuria) were given 8 
weeks of EMPA 25 mg daily. The investigators found that there 
was an increase in renal afferent resistance in the hyperfiltra-
tors with a reduction in glomerular hydrostatic pressure, but no 
change in renal efferent resistance. These parameters were not 
affected by EMPA in the normal GFR controls. This provides 
some evidence that EMPA could have some renoprotective 
effects and should be investigated further.52
Empagliflozin in type 1 diabetes
Empagliflozin may play a role in the treatment of type 1 
diabetes. A recent expert opinion paper summarized the 
potential use of SGLT2 inhibitors in patients with type 1 
diabetes.53 Early studies have shown that use of SGLT2 
inhibitors in type 1 diabetes can reduce HbA
1c
 in 8 weeks 
by 0.4% in those with a baseline of 8.0%. Further, there 
was a statistical reduction in symptomatic hypoglycemia 
and total insulin dose. Mean urinary glucose excretion 
increased from 19 g/24 h to 134 g/24 h. Weight decreased 
by 2.7 kg, and there was also a reduction in waist circumfer-
ence of 3.8 cm. There were two reported cases of diabetic 
ketoacidosis, but they were associated with a pump failure 
and an episode of gastroenteritis.51 This appears to be a 
significant finding that may be related to normoglycemia 
and relative insulinopenia. This is currently under further 
investigation.
Recently, it was shown that SGLT2 inhibition attenu-
ated renal hyperfiltration in subjects with type 1 diabetes 
by affecting tubular glomerular feedback mechanisms and, 
potentially, by its effects on nitric oxide.54,55 Further study 
is needed to determine the safety and long-term efficacy of 
this medication in type 1 diabetes mellitus.
Clinical summary of EMPA
The SGLT2 inhibitors are a welcome addition to the dia-
betes treatment armamentarium. EMPA addresses hyper-
glycemia from a noninsulin centric manner, which can be 
complementary to other agents and can be used even in 
those who no longer make insulin. Further, EMPA appears 
to have significant nonglycemic benefits including weight 
loss, reduction in blood pressure, and reduction in uric acid. 
This is balanced by minor changes in lipid parameters and 
an increase in urinary tract and genital mycotic infections. 
While it was suspected by some physicians (including 
the authors of this paper) that glucosuria would result in 
adverse renal consequences, early studies actually support 
renal benefit from SGLT2 inhibitors from reduced renal 
hyperperfusion and reduction in protein excretion. With 
this profile EMPA and the other SGLT2 inhibitors are 
significant additions to the market for diabetes treatment. 
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This is reflected by inclusion of this class of medications 
in the 2015 American Association of Clinical Endocrinolo-
gists treatment guidelines.56 While the role of these agents 
in type 1 diabetes is unclear, anecdotal reports suggest that 
when used carefully these agents have a significant clinical 
benefit in type 1 diabetes.
Conclusion
Empagliflozin (along with the other SGLT2 inhibitors) is a 
novel addition to treatment of type 2 diabetes. Empagliflozin 
has glycemic and nonglycemic benefits. Glycemic benefits 
are obvious with evidence based on lowering an HbA
1c
 in 
an insulin-independent mechanism. Nonglycemic benefits 
include weight loss, blood pressure lowering, and decreased 
urinary protein excretion.
Diabetes is a progressive disorder, and combination 
therapy is expected as the disease progresses. Reducing 
the medication burden can help to improve adherence to 
complicated medication regimens. Glyxambi® is a novel 
combination therapy option that includes new treatment 
pathways that do not rely on intact insulin secretion. Current 
guidelines recommend combination therapy early in type 2 
diabetes therapy to address the variety of pathophysiologic 
mechanisms.51 Conversely, the cost of these agents may be 
prohibitive for some patients. Depending on drug cover-
age and generic availability, cost should be considered as 
increased cost could cause decreased adherence and disease 
management.
SGLT2 inhibitors may be seen in T2DM patients who 
have failed to reach HbA
1c
 goals with single drug therapy 
with metformin and life style changes. The use of SGLT2 
inhibitors can be explored in patients who may need assis-
tance with weight loss and potential improvement in blood 
pressure. They may be tried as an initial add-on to metformin 
or, in weight loss, or may be used after failure of a GLP-1. 
These should not be used in patients with renal failure, those 
at increased risk of candidiasis infections, or those at risk 
for hypotension.
In the future, SGLT2 inhibitors may be found in addi-
tional combination products. They may be found useful in 
patients with type 1 diabetes. Further studies are needed to 
explore further benefits or risks with SGLT2 inhibitors.
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